NEW YORK (GenomeWeb) – Cynvenio Biosystems said today that it has signed four new distribution agreements for its ClearID line of liquid biopsy tests, making the assays available immediately for patients in Israel, Greece, Argentina, and South Korea.
Pronto Diagnostics will market ClearID in Israel, Karyo in Greece, ProgeniTest in Argentina, and Bio-Medical Science in South Korea.
Cynvenio will continue to perform the tests in its CLIA lab for now. But the company's CEO André de Fusco said that in the future, labs may be able to install the firm's automated liquid biopsy platforms in their own facilities.
The ClearID tests, which detect cancer-associated mutations in both circulating tumor cells and circulating cell-free DNA, are designed for cancer patients undergoing treatment and those who require follow-up testing at regular intervals after completion of therapy. The menu includes separate sequencing panels optimized for breast, colon, and lung cancer.